Singapore, March 3, 2026 — Terumo Blood and Cell Technologies (Terumo BCT) today announced the launch of its new CGT Ecosystem Blueprint — a practical, collaborative approach designed to help cell and gene therapy (CGT) developers in the Asia-Pacific (APAC) region move from early development to scalable, repeatable delivery.

CGT activity is accelerating across APAC, but many programs face persistent challenges in translating scientific progress into consistent, scalable operations. These include fragmented workflows, high operating costs, shortages of GMP-trained talent, and variation in regulatory and manufacturing readiness between markets.

Rather than focusing on individual technologies or isolated process steps, the CGT Ecosystem Blueprint provides a clear map of how critical capabilities, workflows, and partnerships must come together - from cell collection and processing through clinical readiness - to simplify complex workflows, and support more cost-efficient, scalable CGT development and manufacturing.

Terumo BCT is applying the Blueprint in collaboration with regional partners and CGT developers across multiple real-world use cases, including CiRA Foundation to co-develop standardized induced pluripotent stem cell (iPSC) workflows; Eureka Bio and GenScript to integrate end-to-end CAR-T manufacturing processes; and with KBIOHealth and ACTRIS to address regional GMP training and implementation capabilities.

In addition, collaborations with clinical-stage CGT developers, including Precision Bio and Taiwan Bio, reflect real-world execution decisions made under clinical manufacturing constraints. These partners, scanning CAR-T and Treg modalities, apply integrated workflows to address limitations in existing execution models, providing practical validation of clinical readiness, workflow robustness, and scalability under real operating conditions.

Together, these collaborations demonstrate how integration across technologies and partners can reduce operational complexity and cost and enable clear pathways to clinical and manufacturing readiness across diverse operating models in APAC.

“The APAC CGT landscape is maturing, with innovators increasingly building for both local impact and global expansion,” noted Wenyan Leong, Ph.D., Director for APAC Commercial and Global Strategic Partnerships. “Terumo BCT is helping these developers future-proof their operations by providing the same world-class automation and standardization used in the world’s leading markets. Our partners understand that navigating the path to commercialization and clinical delivery requires moving beyond manual, fragmented processes toward integrated, high-quality manufacturing solutions. Our Ecosystem Blueprint acts as the operational foundation, offering the pre-validated pathways and partner networks that transform regional progress into global commercial reality in a practical, scalable way.”

Terumo BCT designed its CGT Ecosystem Blueprint around three core pillars: Fit-for-purpose workflows adaptable to different CGT modalities and development stages; integrated capability and capacities that enable simplified GMP compliant workflows, reduced variability and operational cost as programs scale; and collaborative execution models that align developers, technology providers, and regional partners around shared readiness goals.

“Our focus is not on offering a one-size-fits-all solution, but on enabling CGT developers to build systems that work in their specific environments,” said Lei Li, Vice President, APAC Commercial of Terumo BCT. “By making ecosystem design more explicit, we aim to support more predictable scale-up and, ultimately, broader patient access to advanced therapies.”

As CGT programs continue to expand across APAC, Terumo BCT is establishing its CGT Ecosystem Blueprint as a reference point for organizations seeking to move beyond fragmented approaches toward more coordinated, scalable CGT delivery.

###

About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers, and private medical practices. Our customers are based in over 160 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colorado, U.S.A., along with four regional headquarters, eight manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.